Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer

Shuyue Jiao¹, Xin Zhang², Dapeng Wang³, Hongyong Fu³, Qingxin Xia³

¹Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; ²Department of Pathology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, People’s Republic of China; ³Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University; Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence Diagnosis, Zhengzhou, People’s Republic of China

Correspondence: Qingxin Xia; Hongyong Fu, Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University; Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence Diagnosis, Zhengzhou, People’s Republic of China, Email tudou414135404@163.com; dlxiaoyong@126.com

Introduction: Small cell lung cancer (SCLC), an aggressive subtype of lung cancer characterized by the development of neuroendocrine tumors, is prone to distant metastasis, resistant to platinum-based drugs and has a poor prognosis. The development of next-generation sequencing technology (NGS) has led to the identification of many genetic alterations in SCLC. Few druggable targeted molecules can be used in clinical practice. Currently, NGS is widely employed in routine clinical practice of non-small cell lung cancer to assist in therapeutic options and prognosis evaluation. This study aims to investigate genes involved in small cell lung cancer (SCLC), their occurrence and their significance in clinical events.

Methods: Tumor tissue specimens from 18 Chinese SCLC patients were collected through a 520 cancer-related genes panel for next-generation sequencing. First, the association between sequence results and clinical outcomes was examined. Subsequently, data on clinical pathology and sequencing results were analyzed.

Results: The Kaplan–Meier curve displayed a significant reduction in PFS for SCLC patients with LRP1B or MAP3K13 mutations. Overall survival (OS) of SCLC patients with MSH6 mutation was significantly higher than those with SPEN mutation.

Conclusion: Next-generation sequencing demonstrates that the genetic landscape of SCLC. Mutation status of LRP1B, MAP3K13, MSH6 and SPEN has prognostic significance, which might be potential therapeutic targets. We found possible genes and related signaling pathways that affect metastasis. These results can improve our understanding of the mutation characteristics of SCLC and identify potential biomarkers to guide targeted therapies.

Keywords: small cell lung cancer, next-generation sequencing, genetic alteration, tumor mutation burden, clinical significance

Introduction

Cancer has been one of the leading causes of human death. According to estimates, more than 220 thousand new cases of lung cancer will occur in the United States in 2020.¹ In general, lung cancer is subdivided into two categories, of which small cell lung cancer (SCLC) represents about 13–15%. At diagnosis, about 80% of patients with SCLC are in an advanced stage and cannot undergo surgery.²

SCLC is a highly heterogeneous malignant neuroendocrine tumor.³ Small cell transformation has been demonstrated to be one of the ways in which non-small cell lung cancer (NSCLC) develops resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), leading to a poor prognosis.⁴ Although TP53 and RB1 are tumor suppressor genes with high incidence, few genetic driver events have been reported.⁵ Recent evidence reveals that immune checkpoint inhibitors (ICIs) and specifically programmed death ligand 1 inhibitors combined with standard platinum/etoposide can enhance progression-free survival with minimal adverse effects in patients with extensive SCLC.⁶,⁷ Furthermore, recent evidence shows that co-stimulatory B7-H3 may act as an independent prognostic indicator for SCLC cases, which might provide a theoretical basis for subsequent research targeting B7-H3.⁸,⁹
FOXM1 is crucial for SCLC tumorigenesis and is associated with a poor prognosis. After standard chemotherapy, patients with high FOXM1 expression had shorter progression-free survival compared to those with low FOXM1 expression (3.90 vs 8.69 months). In vitro experiments and experiments on xenograft (PDX) models derived from SCLC patient-derived xenograft reveal that pharmacological inhibition of DHODH can suppress the cell viability. Therefore, in SCLC treatment, DHODH has been a promising target.

SCLC is prone to develop chemoresistance due to its intratumoral heterogeneity. Despite recent advances, SCLC remains the most lethal lung cancer with limited therapeutic options. Studies report that patients with SCLC have a poor prognosis, except for a minimal number of early-stage cases.

Accumulated studies demonstrate that SCLC is a highly heterogeneous tumor, although fewer genetic colonies have been reported in comparison to NSCLC. Transcriptomic analyses reveal four different molecular subtypes, including SCLC-A driven by the transcription factor ASCL1, SCLC-N driven by NEUROD1, SCLC-Y by YAP1, and SCLC-P by POU2F3, allowing for more targeted therapeutic approaches. Subsequent studies confirmed that a unique YAP1 subtype did not exist, and an inflamed subtype of SCLC (SCLC-I) was recently proposed to replace YAP1 subtype. Although SCLC-I subtype experienced the greatest benefit from immune checkpoint inhibitor therapy, the clinical significance of this molecular subtyping in guiding treatment and estimating prognosis remains limited to other standard SCLC treatments.

The development of next-generation sequencing technology (NGS) has led to the identification of many genetic alterations in SCLC, including TP53 and RB1 inactivation and frequent chromosomal abnormalities (deletion 3p). In addition to the inactivated Notch pathway, MYC family amplification has a high incidence. Few druggable targeted molecules can be used in clinical practice. Currently, NGS is widely employed in routine clinical practice of non-small cell lung cancer to assist in therapeutic options and prognosis evaluation. Therefore, it is essential to investigate the genetic characteristics of SCLC and their clinical implications.

In this study, 18 cases of pathologically proven SCLC cases were sequenced using a panel of 520 cancer-related genes. The average median sequencing depth of the samples was 1260x. The average median q30 ratio of the samples was 91%, and all samples are qualified. Analyzing the sequencing results and pathological data revealed some genetic variants with distinctive characteristics.

SCLC presents a distinctive mutation spectrum compared to adenocarcinoma. In our cohorts, results reveal 72% co-occurring TP53/RB1 mutations. Furthermore, in the samples of small cell lung cancer, the core 8 gene was not detected. In SCLC, the frequency of gene mutations is significantly lower than in adenocarcinoma. The mutation frequency of RB1, MSH6, KDR, IL7R, ATRX, EPHB1, PDGFRα, and KIT in SCLC is markedly higher than those in lung squamous cell carcinoma. Due to the small sample size, it might be affected by some random factors.

**Materials and Methods**

**Patients and Sample Collection**

Patients diagnosed with SCLC at Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, were enrolled in this study after obtaining informed consent. Biopsy specimens of advanced stage SCLC were obtained from the Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University. The study protocols were approved by the institutional ethics review board (Ethics Review Committee, Zhengzhou University). While collecting specimens for analysis, we complied with the declaration of Helsinki (2013 Edition) and relevant regulations. Additionally, the clinical characteristics were recovered in this research.

**DNA Isolation and Capture-Based Targeted DNA Sequencing**

DNA extraction and targeted sequencing were performed in Burning Rock Biotech as described in the previous protocol. In brief, formalin-fixed, paraffin-embedded (FFPE) specimens were used for DNA extraction through QIAamp DNA kit (Qiagen, Germany). Subsequently, DNA purification, hybridization, and amplification were performed. Target capture was conducted through a commercial 520 genes panel (OncoScreen Plus). The quality of fragments was determined using a Bioanalyzer 2100 (Agilent Technologies, USA). Finally, the samples were sequenced via the platform of nextseq 500 (Illumina, Inc., USA).
Sequence Data Analysis and Tumor Mutation Burden (TMB) Calculation
The reference genome Hg19 was used through Burrows-Wheeler Aligner version 0.7.10. Subsequently, sequence alignment and variant calling were performed through programs including varscan version 2.4.3 and the genome analysis tool kit version 3.2. The genes variants were annotated with ANNOVAR. The structural variations (SVs) were analyzed using Factera version 1.4.3.

It should count as mutations that non-synonymous single nucleotide variants (SNVs) and indels in the coding sequences and two adjacent base pairs around these regions, while hot mutation, copy number variations (CNVs), structural variations (SVs), and SNPs were excluded.

The size of coding sequences required to estimate TMB is 1.003 MB in the 520 gene panel. The MB per patient was calculated using the following formula.

\[
\text{TMB} = \frac{\text{mutation count (except for CNV, SV, SNPs, and hot mutations)}}{1.003 \text{ Mb}}
\]

Follow-Up and Statistical Analysis
Table 1 lists the clinical and pathological information of SCLC patients. Prospective follow-up was conducted through routine hospital visits or telephone calls. Once every three months, trained medical staff made telephone calls to patients or their family members until death or the last follow-up. The follow-up data of this cohort is included in the Supplementary Materials. Overall survival (OS) was estimated from the day of SCLC diagnosis to the day of death from any cause and was analyzed using Kaplan–Meier estimates and Log rank test. The correlations between categorical variables were calculated using Chi-squared and Fisher’s exact tests. Statistical analyses were performed using SPSS23.0, and P ≤ 0.05 was considered statistically significant.

| Table 1 Clinicopathological Characteristics of the 18 SCLC Patients |
|--------------------------|---------|-------|
| N/Median | %/Range |
| Case | 18 |
| Ages (years) at diagnosis | 60.5 | 47.0–74.0 |
| Gender | | |
| Male | 14 | 77.8% |
| Female | 4 | 22.2% |
| Smoking history | | |
| Yes | 12 | 66.7% |
| No | 5 | 27.8% |
| Null | 1 | 5.6% |
| Period of diagnosis | | |
| 2010s | 18 | 100% |
| Specimen source | | |
| Primary biopsy | 6 | 33.3% |
| Metastatic biopsy | 12 | 66.7% |
| Clinical stage (VASOG) | | |
| Limited stage | 0 | 0 |
| Extensive stage | 18 | 100% |
| Optimal treatment response | | |
| Partial remission (PR) | 12 | 66.7% |
| Stable disease (SD) | 4 | 22.2% |
| Progression disease (PD) | 2 | 11.1% |
| Vital status at last follow-up | | |
| Deceased | 17 | 94.4% |
| Alive | 1 | 5.6% |
Results

Next-Generation Sequencing Shows the Genetic Landscape of SCLC

Capture-based targeted sequencing was performed by Burning Rock Biotech, Guangzhou, China. The average median sequencing depth of the samples was 1260x, consistent with expectations. The average median q30 ratio of the samples was 91%, and all samples were qualified (Supplementary Figure 1). The deletion of the tumor suppressor genes TP53 and RB1 has long been recognized as a common mutation in SCLC. Out of 18, 13 patients showed a co-mutation of TP53 and RB1, reaching a mutation rate of 72%, and the remaining five patients were found with wild-type RB1 as displayed in Figure 1A. Other frequent mutant genes are LRP1B, FAT3, KMT2D, KDR, PTEN, SPTA1, MSH6, Bcl6, EPHB1, etc. Figure 1B illustrates the distribution of identified mutations in SCLC.

Genetic Alteration in SCLC Specimen Was Different from That in Adenocarcinoma and Squamous Cell Carcinoma

The genetic alteration observed in our cohort was in accordance with the SCLC database of Burning Rock Biotech (RS_SCLC) (Figure 2A). Figure 2A includes genes detected in at least three samples. The gene mutation frequency in this cohort did not differ significantly from that in RS_SCLC database.

The genetic differences between SCLC and non-small cell lung cancer were further analyzed (Figure 2B) to explore the molecular genetic characteristics of SCLC. In comparison with NSCLC (adenocarcinoma and squamous cell carcinoma), the mutation spectrum of SCLC differed significantly from the adenocarcinoma database of Burning Rock Biotech (RS_LUAD). Neither the core eight gene nor the frequent mutations in SCLC were detected in adenocarcinomas. Compared to Burning Rock Biotech’s database of squamous cell carcinoma (RS_LUSC), the mutation frequency of genes RB1, MSH6, KDR, IL7R, ATRX, EPHB1, PDGFRA, and KIT was significantly higher. Considering the small sample size, other factors might affect it.

Furthermore, a single nucleotide variation analysis revealed that C > A mutations were more frequent in SCLC, whereas C > T mutations were significantly lower, as illustrated in Figure 2C. Moreover, we analyzed the gene copy number variation (CNV) and tumor mutation burden (TMB) in our cohorts (Figure 3). There was no significant difference in gene copy number variation (CNV) between the cohorts of SCLC group and RS_LUSC group (P =
In contrast, there was a significant difference between SCLC and RS_LUAD groups (P = 0.014). In terms of tumor mutation burden (TMB), there was no significant difference between cohorts of SCLC and RS_LUSC groups (P = 0.80), whereas there was a considerable difference between SCLC and RS_LUAD groups (P = 0.003). In general, SCLC showed higher copy number amplification and TMB compared to lung adenocarcinomas.

Part Mutant Genes are Related to Clinical Factors to Some Extent

In the final analysis, we examined the association between gene mutation and clinicopathological data, including gender, smoking, specimen origins, metastasis site, progression-free survival and overall survival (Figure 4). The criteria for gene
inclusion were as follows: a. genes detected in at least three samples, b. clinical factors with at least three statistics, c. baseline sample data were included for analysis. The results revealed a significant correlation between several mutant genes and clinical factors. The Kaplan–Meier curve showed that patients with LRP1B (Figure 5A) or MAP3K13 (Figure 5B) mutation exhibited significantly shortened PFS. Moreover, SCLC patients with MSH6 mutation had significantly longer OS (Figure 5C), while the OS decreased significantly in patients with SPEN mutation (Figure 5D). In conclusion, MSH6 mutations are associated with a better prognosis than SPEN mutations. The results of this study may help to diagnose and treat Chinese SCLC patients.

The proportion of mutant-PIK3CA was higher in patients with bone metastases (P = 0.012), and the proportion of mutant-FAT1 was higher in patients with liver metastases (P = 0.044), as displayed in Figure 6. Of 18, five patients eventually developed bone metastases; three were detected with PIK3CA mutation, while five of the patients with liver metastases were detected with FAT1 mutation. Based on these results, it can be concluded that related signaling pathways could play a role in regulating organ-specific metastasis.

The signaling pathways based on KEGG involved in mutant genes were analyzed (Figure 7). A pathway is deemed mutant when at least one sample has a mutation in it. Signaling pathways with statistical correlations are listed in Table 2, which requires further investigation. The results indicated that HIF1 signaling pathway, estrogen signaling pathway, chemokine signaling pathway and T cell receptor signaling pathway contributed to bone and lymph node metastasis. Additionally, signaling pathways linked to PFS and OS were identified, and these findings may provide genetic explanations for clinicopathological features.

### Table 2: Signaling Pathways Association with OS, PFS, and Mutations

| Pathway                      | OS (0.6) | OS (1.45) | PFS | TMB | TMB, fac | CNV | RICTOR | GRIN2A | SPEN | NTRK3 | NOTCH1 | KIT | TP63 | MAP3K13 | PIK3CA | KMT2C | IL7R | FAT1 | PDGFR | EPBB1 | BCL6 | MSH6 | SPTA1 | PTEN | KDR | KMT2D | FAT3 | LRP1B | RB1 |
|------------------------------|----------|-----------|-----|-----|---------|-----|--------|--------|------|-------|--------|-----|------|---------|--------|-------|------|------|------|------|------|------|------|------|------|------|------|
| HIF1 signaling               | 0.21     | 0.158     |     | 0.533| 0.533  | 0.262| 0.583  | 0.522  | 0.108| 0.167 | 0.167  | 0.245| 0.163| 0.524   | 0.524  | 0.524 | 0.108| 0.167| 0.167| 0.167| 0.167|
| Estrogen signaling           | 0.21     | 0.333     |     | 0.533| 0.533  | 0.262| 0.583  | 0.522  | 0.108| 0.167 | 0.167  | 0.245| 0.163| 0.524   | 0.524  | 0.524 | 0.108| 0.167| 0.167| 0.167| 0.167|
| Chemokine signaling          | 0.21     | 0.333     |     | 0.533| 0.533  | 0.262| 0.583  | 0.522  | 0.108| 0.167 | 0.167  | 0.245| 0.163| 0.524   | 0.524  | 0.524 | 0.108| 0.167| 0.167| 0.167| 0.167|
| T cell receptor signaling    | 0.21     | 0.333     |     | 0.533| 0.533  | 0.262| 0.583  | 0.522  | 0.108| 0.167 | 0.167  | 0.245| 0.163| 0.524   | 0.524  | 0.524 | 0.108| 0.167| 0.167| 0.167| 0.167|

**Figure 4**: The correlation between mutant gene and clinicopathological data including gender, smoking, specimen origins, metastasis site, and progression free survival and overall survival. Red indicates statistically significant differences (p < 0.05).
Discussion

SCLC in the early stages is sensitive to radiotherapy and chemotherapy. In most patients, satisfactory treatment results cannot be achieved due to the disease’s early progression, recurrence, and chemotherapy resistance. Despite recent advances in SCLC, even on standard platinum-containing two-drug chemotherapy combined with immunization, survival did not exceed two years. Nitin Roper et al disclosed that different transcriptional SCLC subtypes could experience clinical benefit to ICIs, as was Notch signaling activation, which might provide the means for more effective application of ICIs in SCLC. Chemo-immunotherapy has become the preferred initial treatment for advanced SCLC, but only a small subset of SCLC patients’ benefits from ICIs, and there is an urgent need for biomarkers with efficient prediction.

SCLC has long been considered to have higher genomic instability than other types of cancer. The inactivation of TP53 and RB1 occurs early in the course of SCLC. Inactivation of RB1 allows cells to enter the cell cycle, while TP53 loss can prevent cell cycle arrest and apoptosis. Amplification of Myc family members may enhance cell proliferation, while ASCL1 promotes neuroendocrine fate.

Figure 5 Kaplan–Meier curve indicated that SCLC patients with LRP1B (A) or MAP3K13 (B) mutation had significantly shorter PFS. SCLC patients with MSH6 mutation had significantly longer OS (C) while OS was significantly shorter in patients with SPEN mutation (D).
Furthermore, studies have found that histone modification is highly prevalent in SCLC. Overall, these genetic alterations result in replication stress in SCLC, providing a potential direction for gene intervention therapy. Therefore, the study examined various gene mutations associated with SCLC and the effects of those mutations on the pathogenesis of clinical events and their prognosis. In the cbioportal site, we observed whole-genome sequencing of 120 small cell lung cancer (SCLC) tumour samples and matched normal materials.

It is worth mentioning that Kaplan–Meier curve suggested that SCLC patients with LRP1B or MAP3K13 mutation had shorter PFS in our study. LRP1B (low-density lipoprotein receptor-related protein 1b) is a putative tumor suppressor.

Figure 6 The proportion of mutant-PIK3CA is higher in patients with bone metastases (A), the proportion of mutant-FAT1 is higher in patients with liver metastases (B).

Figure 7 The correlation between signaling pathways involved in mutant genes (based on KEGG pathway) and clinicopathological data including gender, smoking, specimen origins, metastasis site, and progression free survival and overall survival. Red indicates statistically significant differences (p < 0.05).
Recent evidence suggests that LRP1B might be a genetic marker for immune checkpoint inhibitors (ICI) in multiple types of cancers. However, nuclear LRP1B, which was released by the intracellular LRP1B domain and transported to the nucleus, increased the invasion activity of breast cancer cells by upregulation of NEAT1. Further studies are required to understand the molecular significance of LRP1B in SCLC progression. MAP3K13 (encoding LZK) is an amplified driver gene in head and neck cancer cells and plays a crucial role in maintaining mutant p53 expression. Qiang Zhang revealed a regulatory pathway that supervised Myc protein stability via MAP3K13-TRIM25-FBXW7α signaling axis, suggesting a potential therapeutic target for cancers that over-express Myc. Considering that MAP3K13 is a targetable oncogenic kinase, its clinical application deserves further investigation in SCLC.

Researchers found that MSH6 mutations have a better prognosis compared to SPEN mutations. DNA mismatch repair genes (MMR) function in maintaining genomic stability. The dysfunction of MMR genes could lead to accumulation during the repair process of DNA and lead to gene instability and overexpression of cancer-related genes, causing tumor initiation and progression. Nine MMR genes related to human mismatch repair have been isolated from human bacteria. MMR is a bacterial MUTS homologue and mainly forms a mismatch complex with MSH2 (MSH2-MSH6) to play a role in mismatch repair. SPEN family transcriptional repressor (SPEN), also known as SMART/HDAC1-related repressor protein, can regulate transcription and is essential for X chromosome inactivation. Multiple studies have demonstrated that SPEN can perform different functions in tumorigenesis. SPEN mutation alters a protein complex that represses the transcription of chronic lymphocytic leukemia NOTCH1 target genes. SPEN induces miR-4652-3p expression by activating PI3K/AKT/c-JUN signaling to target HIPK2. High levels of SPEN RNA are associated with early metastasis in two independent cohorts of 77 (HR 2.25, P = 0.03) and 170 (HR = 2.23, P = 0.004) patients with ERα-negative breast cancer. In contrast, SPEN is a tumor-suppressor gene that may be clinically useful as a predictive biomarker of tamoxifen response in ERα-positive breast cancers. In colon cancer, it acts as an oncogene for its pathogenesis, since it positively regulates Wnt signaling. However, the molecular mechanism of SPEN in SCLC remains unknown. In our cohort, the OS of SCLC patients with SPEN mutation decreased significantly, indicating that SPEN could be used as a prognostic biomarker.

Table 2 The Clinical Factors are Associated with Signaling Pathway Based on KEGG Pathway to Some Extent

| Clinical Factors | Related Signaling Pathway Based on KEGG |
|-----------------|----------------------------------------|
| Gender | Mismatch repair signaling pathway |
| Bone metastasis | T cell receptor signaling pathway, HIF1 signaling pathway, Estrogen signaling pathway, Chemokine signaling pathway |
| Lymph node metastasis | T/B cell receptor signaling pathway, HIF1 signaling pathway, Estrogen signaling pathway, Chemokine signaling pathway |
| PFS | ErbB signaling pathway, T/B cell receptor signaling pathway, Estrogen signaling pathway, NK cell mediated cytotoxicity signaling pathway, Chemokine signaling pathway, Progesterone mediated oocyte maturation, cAMP signaling pathway |
| OS | Mismatch repair signaling pathway |

PI3K/Akt-mediated pathways have been implicated in many tumors. PI3KCA is a P110 catalytic subunit of phosphatidylinositol-3 kinases (PI3Ks), which encodes the PI3KCA protein, namely PI3KP110α. PI3KCA plays a role in multiple signaling pathways and controls cellular functions. Among them, PI3KCA encoding PI3KP110α is the only oncogenic gene with somatic mutation among the members of the PI3K family found at present. About 4/5 mutations of PI3KCA occur in two hot spots, the helix region (Exon 9) and the kinase region (Exon 20). PI3KCA has been identified as an oncogene based on its function and genetics. In tumor cells, the pathogenic mutation of PI3KCA causes abnormal encoding of the p110α subunit that leads to continuous activation of PI3K enzyme. Furthermore, it can activate the downstream Akt, causing independent cell proliferation and enhancing the ability of cells to metastasize. A series of PIKK3CA mutations have been reported in various cancer lines, including SCLC (3.4–4.3%), colorectal cancer (30–40%), ovarian cancer, thyroid, cancer, gastric cancer, and breast cancer (7–40%). This gene has also
been targeted in previous studies of SCLC. Triciribine, a small-molecule Akt inhibitor, was found to act as a pathway inhibitor and was more sensitive to SCLC types with PIK3CA mutations.\textsuperscript{56} In this study, three samples had PIK3CA mutations, and all of them had bone metastases, resulting in a poor prognosis for the patients. Further studies are needed to understand how this gene could improve the treatment of patients with SCLC.

FAT1 is a member of the cadherin superfamily, which encodes procadherin and is frequently mutated in human cancers, especially squamous cell carcinoma.\textsuperscript{57,58} Similarly, our results also showed that nonsense mutations of FAT1 are common and can cause loss of gene function. Previous studies have linked FAT1 mutations to poor outcomes in cancer patients. Recurrent somatic mutation of FAT1 in multiple human cancers could result in aberrant Wnt signaling activation, thus promoting the tumor progression.\textsuperscript{59,60} Studies have demonstrated that FAT1 can encode a protein that binds to β-catenin and antagonizes β-catenin to enter cells to target and activate Wnt that can inhibit cell proliferation and tumor growth.\textsuperscript{61} The experiments on constructed mouse models of skin squamous cell carcinoma and lung cancer found that loss of FAT1 can inhibit adhesion and promote epithelial to mesenchymal cell transformation (EMT) and thus promote tumor genesis, development and metastasis.\textsuperscript{62} From an independent International Cancer Genome Consortium dataset, FAT1 mutation in oral cancer co-occurred with the top mutated genes TP53 and CASP8. Poor overall survival or progression-free survival was observed in patients with FAT1 mutation or altered HER3_pY1289, IRS1, or CAVEOLIN. Pathway analysis revealed dominant ERBB/neuregulin pathways mediated by FAT1 mutations in HNSCC.\textsuperscript{63} FAT1 plays various roles in different types of cancer and can be used as an oncogene or a tumor suppressor gene. Studies have confirmed that the expression of FAT1 in liver cancer is higher and acts as a tumor protector than in nontumor liver tissue.\textsuperscript{64,65} Our results show that patients with FAT1 mutation were more prone to liver metastasis, an alternative therapeutic target for SCLC patients. Farago et al reported that combining olaparib and temozolomide in relapsed SCLC could significantly improve the prognosis of SCLC patients.\textsuperscript{66} After that, they identified a molecular signature predictive of the response to this regimen. Olaparib is PARP inhibitor and has been proved to be effective for BRCA-mutated metastatic breast cancer and ovarian cancer.\textsuperscript{57,68} We found BRCA2 mutant in our SCLC cohort, which might suggest better sensitivity to olaparib.

**Conclusion**

Next-generation sequencing demonstrates that the genetic landscape of SCLC is different from that of adenocarcinoma and squamous cell carcinoma. Part mutant genes are linked to clinical factors to some extent. Mutation status of LRP1B, MAP3K13, MSH6 and SPEN has prognostic significance, which might be potential therapeutic targets. We found possible genes and related signaling pathways that affect metastasis. Oncologists might acquire important information to assist in therapeutic options and prognosis evaluation, and SCLC patients might benefit from NGS in clinical practice, and the underlying mechanism deserves further investigation.

**Acknowledgment**

We are grateful to all peer reviewers and editors for their opinions and suggestions.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

This work was supported by grants from Henan Cancer Hospital Doctors’ Initiation Foundation (Grant No. 310103010210962) and Medical Science and Technology Research Program of Henan Province (Grant No. LHGJ20190636). Natural Science Foundation of Henan Province (Grant No.222300420353).
Disclosure
The authors declare that they have no conflicts of interest in this work.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
2. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003;123(1 Suppl):259s–271s. doi:10.1378/chest.123.1_suppl.259S
3. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24(1):70–76. doi:10.1200/JCO.2005.04.1202
4. Offin M, Chan JM, Tenet M, et al. Concurrent RBB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–1793. doi:10.1016/j.jtho.2019.06.002
5. Rudin CM, Brambilla E, Faire-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0
6. Ortega-Franco A, Ackermann C, Paz-Ares L, Califano R. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. ESMO Open. 2021;6(1):100003. doi:10.1016/j.esmoop.2020.100003
7. Tay Ry, Heigener D, Reck M, Califano R. Immune checkpoint blockade in small cell lung cancer. Lung Cancer. 2019;137:31–37. doi:10.1016/j.lungcan.2019.08.024
8. Qiu MJ, Xia Q, Chen YB, et al. The expression of three negative co-stimulatory B7 family molecules in small cell lung cancer and their effect on prognosis. Front Oncol. 2021;11:600238. doi:10.3389/fonc.2021.600238
9. Carvajal-Hausdorf D, Altan M, Velcchi E, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC). J Immunother Cancer. 2019;7(1):65. doi:10.1186/s40425-019-0540-1
10. Liang SK, Hsu CC, Song HL, et al. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis. Oncogene. 2021;40:4847–4858.
11. Li L, Ng SR, Colón CI, et al. Identification of DHODH as a therapeutic target in small cell lung cancer. Sci Transl Med. 2019;11(517). doi:10.1126/scitranslmed.aaw7852.
12. Shue YT, Lim JS, Sage J. Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. Transl Lung Cancer Res. 2018;7(1):21–31. doi:10.21037/tlcr.2018.01.15
13. Saltos A, Shaﬁque M, Chiappori A. Update on the biology, management, and treatment of Small Cell Lung Cancer (SCLC). Front Oncol. 2020;10:1074. doi:10.3389/fonc.2020.01074
14. Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289–297. doi:10.1038/s41568-019-0133-9
15. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation deﬁne four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346–360.e347. doi:10.1016/j.ccell.2020.12.014
16. Gaozdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725–737. doi:10.1038/nrc.2017.87
17. Brägelmann J, Böhm S, Guthrie MR, Mollaouliu G, Oliver TG, Soo MJ. Family matters: how MYC family oncogenes impact small cell lung cancer. Cell Cycle. 2017;16(16):1489–1498. doi:10.1080/15384101.2017.1339849
18. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjeri AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599–1622. doi:10.1016/j.mayocp.2019.01.034
19. Mao X, Zhang Z, Zheng X, et al. Capture-based targeted ultrasequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J Thorac Oncol. 2017;12(4):663–672. doi:10.1016/j.jtho.2016.11.2235
20. Li YS, Jiang BY, Yang JJ, et al. Unique genetic proﬁles from cerebrospinal ﬂuid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol. 2018;29(4):945–952. doi:10.1093/annonc/mdy009
21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–1760. doi:10.1093/bioinformatics/btp324
22. Mckenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–1303. doi:10.1101/gr.107524.110
23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. doi:10.1093/nar/gkq680
24. Newman AM, Bratman SV, Stehr H, et al. FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics. 2014;30(23):3390–3393. doi:10.1093/bioinformatics/btu549
25. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in ﬁrst-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10121):1929–1939. doi:10.1016/S0140-6736(19)32222-6
26. Roper N, Velez MJ, Chiappori A, et al. Notch signaling and efﬁcacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nat Commun. 2021;12(1):3880. doi:10.1038/s41467-021-24164-y
27. Barrows ED, Blackburn MJ, Liu SV. Evolving role of immunotherapy in small cell lung cancer. Semin Cancer Biol. 2022. doi:10.1016/j.semcancer.2022.02.021
28. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–1110. doi:10.1038/ng.2396
29. Muewissen R, Lim SC, Linnolla RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;3(4):181–189. doi:10.1016/S1535-6108(03)00220-4
30. Olsen RR, Ireland AS, Kastner DW, et al. ASCL1 represses a SOX9(+)/neural crest stem-like state in small cell lung cancer. Genes Dev. 2021;35(11–12):847–869. doi:10.1101/gad.348295.121
31. George J, Lim JS, Jang SJ, et al. Comprehensive genomic proﬁles of small cell lung cancer. Nature. 2015;524(7563):47–53. doi:10.1038/nature16464
60. Hsu TN, Huang CM, Huang CS, et al. Targeting FAT1 inhibits carcinogenesis, induces oxidative stress and enhances cisplatin sensitivity through+.

37. ThirumalKumarD, SusmitaB, JudithE, Priyadharshini Christy J, George Priya Doss C, Zayed H. Elucidating the role of interacting residues of the+.

32. Brown LC, Tucker MD, Sedhom R, et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across+.

58. Dotto GP, Rustgi AK. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell. 2016;29(5):622–637. doi:10.1016/j.ccell.2016.04.004

Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.1096502

Meng F, Zhang L. miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition. Exp Cell Res. 2019;374(2):315–322. doi:10.1016/j.yexcr.2018.12.003

Han N, Cheng QY, Chen B, et al. PIK3CA mutations in resected small cell lung cancer. Adv Clin Exp Med. 2016;25(3):397–402. doi:10.17219/acem/25928

Samuels Y, Velecsu VC, Eno K. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221–1224. doi:10.4161/cc.3.10.1164

Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer. 2006;54(2):209–215. doi:10.1016/j.lungcan.2006.07.006

García-Rostán G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199–10207. doi:10.1158/0008-5472.CAN-04-4259

Liu Z, Roberts TM. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle. 2006;5(7):675–677. doi:10.4161/cc.5.7.2605

Shibata T, Kobuk A, Tsuta K, Hirohashi S. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett. 2009;283(2):203–211. doi:10.1016/j.canlet.2009.03.038

Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013;45(3):253–261. doi:10.1038/ng.2538

Dotto GP, Rustgi AK. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell. 2016;29(5):622–637. doi:10.1016/j.ccell.2016.04.004

Santana NO, Lerario AM, Schmerling et al. Molecular profile of Hürthle cell carcinomas: recurrent mutations in the Wnt/β-catenin pathway. Eur J Endocrinol. 2020;183(6):647–656. doi:10.1530/EJE-20-0957

Hsu TN, Huang CM, Huang CS, et al. Targeting FAT1 inhibits carcinogenesis, induces oxidative stress and enhances cispilatin sensitivity through deregulation of LRPS5/WNT2/GSS signaling axis in oral squamous cell carcinoma. Cancers. 2019;11(12):1883. doi:10.3390/cancers11121883

Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129(4):199–221. doi:10.1007/s00432-003-0431-0

Pastushenko I, Mauri F, Song Y, et al. Fat1 deletion promotes hybrid EMT state, tumor stemness and metastasis. Nature. 2021;589(7842):448–455. doi:10.1038/s41586-021-00460-5

Chen Z, Zhang C, Chen J, et al. The proteomic landscape of growth factor signaling networks associated with FAT1 mutations in head and neck cancers. Cancer Res. 2021. doi:10.1158/0008-5472.can-20-3659

Xu J, Wang B, Liu ZT, Lai MC, Zhang ML, Zheng SS. miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene. Math Biosci Eng. 2019;17(2):1534–1547. doi:10.3934/mbe.2020079

Valletta D, Czech B, Spruss T, et al. Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis. 2014;35(6):1407–1415. doi:10.1093/carcin/bgu054
66. Farago AF, Yeap BY, Stanzione M, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372–1387. doi:10.1158/2159-8290.CD-19-0582

67. Wang XW, Hu N, Cui L, et al. Durable disease-free survival in a patient with metastatic triple-negative breast cancer treated with olaparib monotherapy. Curr Cancer Drug Targets. 2022;22. doi:10.2174/1568009622666220214092207

68. Martin NA, Hanna M, Ehret C, Asiedu G, Jatoi A. Olaparib for ovarian cancer: a single-institution, multi-site qualitative study. Support Care Cancer. 2022. doi:10.1007/s00520-022-06879-w